Stay updated on Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page
- Check14 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check21 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check28 days agoNo Change Detected
- Check43 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check57 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed information about a phase II trial studying nivolumab and ipilimumab for treating renal medullary carcinoma, while adding new identifiers and collaborators related to the study.SummaryDifference58%
- Check64 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4 and has removed the date 2025-03-25 while adding the date 2025-01-13.SummaryDifference0.3%
- Check72 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
Stay in the know with updates to Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page.